La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Forge Group a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Forge Group..

Forge Group (OTC:FIGP) Azioni, Catena delle Opzioni

Forge Group Inc operates as a specialist commercial automobile insurance business. It provides commercial automobile insurance products targeted to owners and operators of taxi cabs, passenger sedans, and other light transportation vehicles, including golf carts and school vans. It manages business through two segments: insurance and commercial real estate investments.

Forge Group Inc

Canaan Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) ("Canaan" or the "Company"), an innovator in crypto mining, today&nbsp;announced that on May 13, 2025, it received a written notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price of its American depositary shares (the "ADSs") was below US$1.00 per share for the last 30 consecutive business days. The Nasdaq notification letter has no immediate effect on the listing or trading of the Company's securities on Nasdaq.
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar-day compliance period, or until November 10, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's ADSs must meet or exceed US$1.00 per share for at least 10 consecutive business days during the 180-calendar-day compliance period.

News

Canaan Receives Nasdaq Notification Regarding Minimum Bid Requirements

Telsey Advisory Group analyst Cristina Fernández reiterated the Market Perform rating on Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) on Friday, raising the price forecast from $20 to $24.
Foot Locker&nbsp;shares rocketed premarket on Thursday after the company disclosed a definitive deal to be acquired by&nbsp;Dick&#8217;s Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) which values Foot Locker&#8217;s equity at around $2.4 billion and&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45431136/dicks-sporting-goods-to-acquire-foot-locker-to-create-a-global-leader-in-the-sports-retail-industr" rel="noreferrer noopener">its enterprise at about $2.5 billion</a>.
As per the deal, Foot Locker shareholders will have the option to receive either $24 in cash or 0.1168 shares of DICK&#8217;S common stock for each share of Foot Locker common stock they own.
Fernández writes that the acquisition is a favorable outcome for Foot Locker shareholders. Why? The acquisition offer is an 86% premium over the prior day&#8217;s closing price. The deal also comes at a time when the company&#8217;s 2025 outlook has weakened. Recall the company&#8217;s disappointing preliminary Q1 results.
Fernández raised the price forecast, aligning with the acquisition offer, and noted that softness seen in February worsened through the quarter, likely due to dampened sentiment following tariff news—reflected in Foot Locker&#8217;s preannounced Q1 comp decline of 2.6% and an EPS loss of 7 cents, both missing consensus.
Fernández revised the 2025 EPS estimate for Foot Locker to $1.20, down from $1.48, below the FactSet consensus of $1.36; alongside a reduced comp forecast of 0.5% versus the earlier 1.5%.
For 2026, the EPS projection was also cut to $1.50 from $1.75, trailing the FactSet estimate of $1.62.
Price Action: FL shares are trading lower by 0.25% to $23.85 at last check Friday.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45472978/stocks-fight-for-fifth-day-of-gains-dollar-rebounds-as-inflation-fears-go-haywire-whats-driving-markets-friday">Stocks Fight For Fifth Day Of Gains, Dollar Rebounds As Inflation Fears Go Haywire: What&#8217;s Driving Markets Friday?</a></li>
</ul>
Image: Shutterstock

Equities

Markets

Analyst Ratings

Movers

Trading Ideas

General

What's Next For Foot Locker? Analyst Says Dick's Deal Is Timely

Most people spend their lives hoping to get rich before they die. Charlie Munger lived long enough to do it — and credited his success to something far less glamorous than genius.
In his <a href="https://www.cnbc.com/2023/11/30/full-transcript-from-cnbcs-charlie-munger-a-life-of-wit-and-wisdom-.html">final interview with CNBC's Becky Quick</a> in 2023, the 99-year-old Berkshire Hathaway vice chairman reflected on the "amazing occurrence" of turning a "piddly start" into a multi-hundred-billion-dollar company alongside Warren Buffett, now 94.
When asked what led to their success, Munger didn't reach for buzzwords or bravado. "We got a little less crazy than most people and a little less stupid than most people. And that really helped us," he said.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
He added that the real secret was simply staying alive long enough to <a href="https://www.benzinga.com/personal-finance/25/04/44913214/charlie-munger-said-you-only-have-to-get-rich-once-but-warned-the-first-100k-is-a-btch-and-the-most-important-step-to-building-wealth">let everything compound</a>: "We were given this much longer time to run than most people… that gave us a long track from our little, piddling start all the way to the 90s."
Munger's trademark style — deadpan, honest, and piercing — was on full display. He admitted he never expected Berkshire to hit $100 million, let alone several hundred billion.&nbsp;
But what they lacked in flashy moves, they made up for in patience and discipline. "We wised up over time," he said, explaining how they grew more skilled at spotting trouble and staying away from it. "We got into better and better companies. We understood more and more of the bad things that could happen… and we avoided them even more – like when we were old than we did when we were young."
This was a man who openly dismissed the investing model made famous by Ben Graham — <a href="https://www.benzinga.com/personal-finance/25/02/43718032/warren-buffett-was-asked-how-a-regular-person-gets-rich-he-detailed-exactly-how-hed-make-30-billion-starting-over-with-only-10000">the very one Buffett once studied</a>. Graham believed you could find a few good deals and hold them for a few years. Munger thought that was shortsighted. "I saw immediately that Graham was wrong," he said. "The real money was in the really great companies, which carried you up, and up, and up, and up, and up."
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
Munger and Buffett <a href="https://www.benzinga.com/news/25/01/42976301/charlie-munger-said-his-family-only-owns-3-stocks-damn-right-theyre-rich-because-diversification-is-for-know-nothing-investors">didn't chase hot stocks or rotate in and out of trades</a>. Instead, they built what Quick called "sit on your ass investing" — a method that involved waiting for only the best opportunities. "You wait for the big, fat pitches to come in," she said. "Yeah, that's correct," Munger replied without hesitation.
But that method, Munger warned, is much harder now. "It's so much harder you can't believe it," he said, explaining that as the Ben Graham strategy gained popularity, the low-hanging fruit vanished. "If you just try and float from one undervalued, bad business into another… it just doesn't work well enough for the people that actually foot him the money to be worth bothering with."
What worked for Munger and Buffett wasn't complicated. It was the <a href="https://www.benzinga.com/personal-finance/25/03/44065682/charlie-munger-shared-advice-for-the-young-but-it-applies-to-all-if-youve-got-anything-you-really-want-to-do-dont-wait-until-youre-93">kind of advice most people ignore</a> because it doesn't sound exciting: think clearly, avoid dumb decisions, and let time work its magic. They didn't try to be brilliant — they just tried not to be stupid. And over the course of nine decades, that was more than enough.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
Image: Shutterstock

Personal Finance

Charlie Munger Said Berkshire's Billions Came From Getting 'Less Crazy And Less Stupid Than Most People' — And Staying Alive Into Their 90s

Jones Trading analyst Soumit Roy downgrades Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) from Buy to Hold.

Downgrades

ONCY

Jones Trading Downgrades Oncolytics Biotech to Hold

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 5 years by 21.77% on an annualized basis producing an average annual return of 37.04%. Currently, Eli Lilly has a market capitalization of $681.71 billion. 
Buying $100 In LLY: If an investor had bought $100 of LLY stock 5 years ago, it would be worth $479.48 today based on a price of $759.00 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747427413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 6900.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 70.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 20.90% at $1.66</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 20.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 11.20% at $0.49</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 9.43% at $1.04</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 6.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 5.77% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 5.55% at $7.34</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 4.39% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 3.53% at $0.38</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 3.44% at $5.13</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 13.04% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 11.11% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 10.89% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 9.38% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 7.63% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 6.59% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 5.66% at $0.83</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 5.36% at $0.68</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 4.33% at $4.46</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 4.04% at $0.95</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

BMMJ

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CLSH

CNBX

CNTMF

CRBP

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CVSI

FFNTF

FUAPF

GNLN

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

RMHB

TCNNF

TLRY

UGRO

YCBD

Cannabis Stock Movers For May 16, 2025

Jefferies analyst Joseph Gallo maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and raises the price target from $215 to $225.

Price Target

PANW

Jefferies Maintains Buy on Palo Alto Networks, Raises Price Target to $225

Jefferies analyst Julien Dumoulin-Smith initiates coverage on MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Buy rating and announces Price Target of $188.

Initiation

Jefferies Initiates Coverage On MasTec with Buy Rating, Announces Price Target of $188

MOVE

Trading Halt: Halted at 4:25:00 p.m. ET - Trading Halt: Halt News Pending

State Street Global Advisors&#8216; latest ETFs in Focus report identifies an interesting discord: an increasing divergence between financial advisors and retail investors in how they view portfolio risk. The report also shows how <a href="https://www.benzinga.com/etfs">ETFs are becoming an important middle ground</a> between these two perspectives.
Although&nbsp;each&nbsp;group&nbsp;recognizes&nbsp;increased&nbsp;uncertainty in&nbsp;the&nbsp;current&nbsp;market, they&nbsp;disagree&nbsp;on&nbsp;risks to&nbsp;focus&nbsp;on&nbsp;and&nbsp;how to&nbsp;manage&nbsp;them. This&nbsp;disagreement&nbsp;highlights&nbsp;the&nbsp;importance&nbsp;of&nbsp;a more&nbsp;holistic&nbsp;risk management&nbsp;approach—one that&nbsp;uses&nbsp;ETFs for both&nbsp;transparency&nbsp;and strategic&nbsp;synergy.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/05/45474787/etfs-with-major-coinbase-stakes-surge-as-coin-prepares-to-join-sp-500">ETFs With Major Coinbase Stakes Surge As COIN Prepares To Join S&amp;P 500</a>
Retail Investors Prioritizing Near-Term, Inflation-Driven Risks
Retail investors are still primarily focused on risks that have tangible and immediate effects on their pocket. The report identifies the top three investor concerns as trade wars and tariffs (44%), recession (37%), and surprise inflation (34%). These apprehensions indicate the economic matters that most immediately influence consumer spending power, investment returns, and savings stability.
Advisors Have A Wider Perspective On Systemic Risks
Conversely, financial advisors pay closer attention to systemic and long-term hazards. They identify recession and growth shocks (34%), geopolitical tensions (31%), and adjustments in government policy or regulation (28%) as key threats to client portfolios. Advisors are also more inclined to follow diversified strategies that include alternative investments, higher cash positioning, and exposure to low-volatility asset classes.
Notably, advisors are using ETFs to access alternative strategies more effectively. More than 75% of advisors intend to expand their usage of alternative ETF strategies in the next 12–18 months. This is a testament that ETFs are becoming indispensable tools for risk-adjusted returns, portfolio resiliency, and asset allocation flexibility.
ETFs As A Convergence Point For Risk Management
ETFs are taking center stage in bridging the gap between advisor strategy and investor sentiment. ETFs are providing accessibility, transparency, and the ability to trade whenever they wish for individual investors. The vast majority of users of ETFs say these funds have made them more informed investors and enhanced their capability in portfolio management.
These advantages indicate ETFs are well suited to act as a risk management solution that harmonizes investor comfort with advisor expertise.
Also Read: <a href="https://www.benzinga.com/25/05/45472683/vontobel-joins-the-active-etf-race-with-global-precision">Vontobel Launches First Active ETF, Bets On High-Quality Global Stocks</a>
Some ETFs That Align With Bridging Investor Caution And Advisor Foresight
iShares U.S. Treasury Inflation Protected Securities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIP#NYSE">TIP</a>)
Why it fits: TIP offers exposure to TIPS, helping hedge against inflation and preserve purchasing power—ideal for investors focused on short-term cost-of-living concerns.
SPDR SSGA Multi-Asset Real Return ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLY#NYSE">RLY</a>)
Why it fits: RLY provides diversified exposure to real assets like commodities, TIPS, and REITs—offering built-in protection against macro and geopolitical risks for advisors seeking alternative, flexible strategies.
First Trust Managed Futures Strategy Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMF#NYSE">FMF</a>)
Why it fits: FMF uses a managed futures strategy to offer non-correlated returns, giving advisors a hedge against volatile markets in an accessible, ETF format.
Conclusion: Constructing Strategic Alignment In A Volatile World
The gap between investor anxiety and advisor foresight has real consequences for portfolio strategy. While investors focus on inflation and trade, and advisors plan for broader macro shocks, ETFs offer common ground for building more resilient portfolios.
Greater investor education and access to transparent, low-cost ETFs can help bridge this divide and strengthen preparedness for market uncertainty.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/05/45457712/move-over-miners-hedge-funds-are-the-new-gold-diggers-ray-dalio-blackrock-goldman-sachs-other">Move Over Miners, Hedge Funds Are The New Gold Diggers &#8230; Ray Dalio, BlackRock, Goldman Sachs, Others Stake Claims In GLD</a></li>
</ul>
Photo: bigjom jom via Shutterstock

ETFs

Investors Fear Tariffs, Advisors Fear Chaos — ETFs Are The Unexpected Middle Ground

Offerings

Tejon Ranch Files For Mixed Shelf Offering Up To $200M

Jefferies analyst Scott Marks maintains Flowers Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>) with a Hold and lowers the price target from $20 to $16.

Jefferies Maintains Hold on Flowers Foods, Lowers Price Target to $16

WEAV

Weave Communications Files For Mixed Shelf Offering; Size Not Disclosed

CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) has outperformed the market over the past 20 years by 5.58% on an annualized basis producing an average annual return of 13.93%. Currently, CSX has a market capitalization of $58.95 billion. 
Buying $1000 In CSX: If an investor had bought $1000 of CSX stock 20 years ago, it would be worth $13,413.28 today based on a price of $31.38 for CSX at the time of writing.
<h3>CSX's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747426537_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Coca‑Cola Consolidated, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) today announced that its 10-for-1 split of the Company's Common Stock and Class B Common Stock has been approved by its stockholders, and shares of the Company's stock are expected to begin trading on a split-adjusted basis at market open on or about May 27, 2025. On May 23, 2025, stockholders will receive nine additional shares for each share of Common Stock or Class B Common Stock held.
The stock split was subject to stockholder approval of an amendment to the Company's Restated Certificate of Incorporation to effect a 10-for-1 forward stock split of the Company's Common Stock and Class B Common Stock and to proportionally increase the number of authorized shares of Common Stock and Class B Common Stock to accommodate the stock split (the "Amendment"). The Amendment was approved by the Company's stockholders at its Annual Meeting of Stockholders on May 13, 2025.

Stock Split

COKE

Coca-Cola Consolidated Stockholders Approve 10-For-1 Stock Split, Trading Begins May 27

On the surface, outside circumstances don't appear favorable for pharmaceutical giant Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which finds itself caught in a political wake. Earlier this week, President Donald Trump signed an executive order aimed at <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">lowering prescription drug prices</a>, posing significant challenges for pharmaceutical companies. Still, with the bad news baked into BMY stock, a potential for a bounce back isn't out of the question.
In a Truth Social post on Sunday, Trump stated that the executive order will implement a "Most Favored Nations" policy. Essentially, the directive will prevent pharmaceutical firms from charging disparate prices across different markets. In theory, then, U.S. consumers will pay no more than what patients from other countries will be charged for the same drug.
Fundamentally, the move will likely have the biggest impact on Medicare Part B drugs, a category that largely consists of outpatient prescriptions and biologicals. Further, the prices of these drugs are directly managed by the Centers for Medicare &amp; Medicaid Services (CMS).
See Also: <a href="https://www.benzinga.com/markets/equities/25/05/45476152/cava-beats-q1-expectations-analyst-names-it-a-top-pick-amid-expansion-push">Cava Beats Q1 Expectations, Analyst Names It A &#8216;Top Pick&#8217; Amid Expansion Push</a>
As it relates to Bristol-Myers Squibb, its cancer drug Opdivo falls under the Part B categorization. This fact puts BMY stock at risk since Trump is seeking to reduce prescription drug prices by "30% to 80%." Setting aside the <a href="https://www.msnbc.com/opinion/msnbc-opinion/trump-drug-price-executive-order-big-pharma-rcna206289">legality</a> of the proposal, a discount of that magnitude would force a reevaluation of the business.
Nevertheless, the shock to the system may present an opportunity for contrarian speculators.
<h2 class="wp-block-heading">A Rare Quantitative Signal May Bode Well for BMY Stock</h2>
Although BMY stock represents one of the stalwarts of the broader healthcare ecosystem, it hasn't always been the most productive security for investors. For example, in the past 52 weeks, shares have only gained less than 6%. And in the trailing five years, BMY is down more than 27%.
Part of the challenge centers on the choppiness of the security. Since January 2019, BMY stock barely demonstrates an upward bias. Specifically, the odds that a long position held for a one-week period will be profitable are only 50.6%. That's not a reliable edge by any means.
However, the long-side probability is not 50.6% across all sentiment regimes. In other words, certain fear and greed cycles may feature probabilities that are much more favorable than the baseline.
As circumstances stand right now, BMY stock is charting a "2-8" sequence: two up weeks mixed with eight down weeks, with a negative trajectory across the period. This bearish-dominated sequence has only materialized 18 times in the past decade. Notably, though, in 61.11% of cases, the following week's price action has resulted in upside, with a median return of 1.19%.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16152538/BMY-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-918453" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16152538/BMY-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16152538/BMY-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16152538/BMY-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16152538/BMY-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Assuming the bulls continue to control the market, a move toward $48 over the next three weeks would be quite reasonable. On the other hand, should the bears assume the wheel, a gradual descent to around $45 may be the downside target.
<h2 class="wp-block-heading">Scalping a Big Payout from a Small Move</h2>
In the open market, BMY stock could deliver a return of about 3%, which isn't anything to write home about. However, it's a different story when traders take advantage of the unique geometry of multi-leg options strategies.
Take, for example, the 47/48 bull call spread expiring June 6. This transaction involves buying the $47 call and simultaneously selling the $48 call. With the credit received from the short call partially offsetting the debit paid for the long call, the net debit paid for this trade comes out to $47. Should BMY stock rise through the short strike price of $48 at expiration, the maximum reward is $53, a payout of nearly 113%.
To be clear, both legs of the 47/48 call spread are out the money, which means that if BMY stock doesn't move at all from here, the entire net debit is at risk of loss. On the other hand, the leverage that options provide allows relatively small moves to translate to big gains.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45466937/us-targets-european-digital-rules-in-free-speech-campaign-defending-american-big-tech" target="_blank" rel="noreferrer noopener">US Slams Europe's Digital Laws, Calls Them A Danger To Free Expression And American Big Tech</a></li>
</ul>
Image: Shutterstock

Options Corner: Political Turmoil Sets Up A Contrarian Call Spread For Bristol-Myers Squibb

HSIC

Henry Schein Completes $250M Of Strategic Investment By Funds Affiliated With KKR

Jefferies analyst Greg Konrad maintains Virgin Galactic Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) with a Buy and lowers the price target from $9 to $8.

SPCE

Jefferies Maintains Buy on Virgin Galactic Hldgs, Lowers Price Target to $8

Grove Collaborative Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) ("Grove" or "the Company"), reports that, on May 15, 2025, it received written notice (the "NYSE Notice") from the New York Stock Exchange ("NYSE") of non-compliance with Section 802.01B of the NYSE Listed Company Manual (the "NYSE Manual"), which requires an average global market capitalization of not less than $50 million over a consecutive 30 trading-day period and stockholders' equity of not less than $50 million.

GROV

Grove Collaborative Holdings Receives NYSE Non-Compliance Notice Over Market Cap & Equity Requirements

Even with Wall Street rallying off April lows, small-cap stocks remain stuck in the mud, with the Russell 2000 still trading near its lowest level relative to the S&amp;P <a href="https://www.benzinga.com/topic/small-caps">500 since December 2000.</a>
The ratio between iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) and SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) continued to hover around levels last seen 24 years ago, a clear sign of investor preference for large, multinational firms amid ongoing macro volatility.
<h1 class="wp-block-heading">Chart: Small Caps Have Never Been This Cheap Relative To Large Caps In A Quarter Of A Century</h1>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16113446/image-204-1024x529.png" alt="" class="wp-image-918167" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16113446/image-204-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16113446/image-204-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16113446/image-204-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16113446/image-204-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16113446/image-204-2048x1058.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h1 class="wp-block-heading">Why Small Caps Lag Behind</h1>
Small companies have consistently trailed large-cap peers throughout 2025, and analyst Michael Gayed, CFA, said there's a clear reason: "These companies are likely to be more negatively impacted by tariffs because of their lesser ability to shift supply chains quickly and the comparative lack of financial resources to be able to handle higher costs."
Large corporations typically possess more diversified operations and pricing power, helping them weather tariff shocks better than smaller, domestically focused peers.
<h1 class="wp-block-heading">Is A Reversal in Sight?</h1>
President Donald Trump's recent U-turn on tariff policy — suspending reciprocal duties with China and reducing trade tensions — has opened the door for a change in market leadership. Investors who had bet against small caps might soon need to rethink their positioning.
"If the Liberation Day tariffs have been largely responsible for small-cap underperformance, wouldn't it stand to reason that a reversal of those policies could inspire them to lead?" Gayed said.
The return to a more stable trade environment may create a short-term tailwind for small stocks, particularly those that derive the bulk of their revenues within the U.S.
<h1 class="wp-block-heading">Longer-Term Catalyst: Deregulation</h1>
Beyond trade policy, the bigger structural catalyst could be deregulation — a central theme in Trump's second-term economic agenda.
Reducing federal red tape, especially in energy and financial services, could provide meaningful relief to small-cap companies that have historically been burdened by compliance costs and bureaucratic hurdles.
Looser regulation may enhance profit margins and boost investor sentiment toward smaller firms that have long struggled under stricter oversight compared to their larger counterparts.
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45468724/emerging-markets-break-out-as-peace-trades-gain-momentum-hartnett-says">Emerging Markets Break Out As &#8216;Peace Trades&#8217; Gain Momentum, Hartnett Says</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Photo: Drozd Irina via Shutterstock

Comments

Forge Group

Forge Group (FIGP) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO